S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80

Adverum Biotechnologies Stock Forecast, Price & News

+0.07 (+6.03%)
(As of 07/6/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
892,024 shs
Average Volume
1.39 million shs
Market Capitalization
$121.49 million
P/E Ratio
Dividend Yield
Price Target

Adverum Biotechnologies MarketRank™ Forecast

Analyst Rating
2.00 Rating Score
184.6% Upside
$3.50 Price Target
Short Interest
6.08% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Acquiring Shares
$111,944 Bought Last Quarter
Proj. Earnings Growth
From ($1.57) to ($1.39) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.63 out of 5 stars

Medical Sector

57th out of 1,433 stocks

Biological Products, Except Diagnostic Industry

8th out of 220 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ADVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Adverum Biotechnologies logo

About Adverum Biotechnologies (NASDAQ:ADVM) Stock

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

ADVM Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
A Bigger Opportunity For Growth…
A smaller stock with a relatively low market cap often outperforms a larger company stock with a much higher market cap… And when an investor is spending fewer dollars for a stock purchase there’s a bigger opportunity for growth. Click Here for Our Top 5 Microcap Stocks.
Adverum Biotechnologies names new CMO
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$7.50 million
Book Value
$3.22 per share


Free Float
Market Cap
$121.49 million

Adverum Biotechnologies Frequently Asked Questions

Should I buy or sell Adverum Biotechnologies stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Adverum Biotechnologies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADVM, but not buy additional shares or sell existing shares.
View analyst ratings for Adverum Biotechnologies
or view top-rated stocks.

What is Adverum Biotechnologies' stock price forecast for 2022?

5 analysts have issued 12-month price objectives for Adverum Biotechnologies' shares. Their ADVM stock forecasts range from $2.00 to $6.00. On average, they predict Adverum Biotechnologies' share price to reach $3.50 in the next twelve months. This suggests a possible upside of 184.6% from the stock's current price.
View analysts' price targets for Adverum Biotechnologies
or view top-rated stocks among Wall Street analysts.

How has Adverum Biotechnologies' stock price performed in 2022?

Adverum Biotechnologies' stock was trading at $1.76 at the beginning of 2022. Since then, ADVM stock has decreased by 30.1% and is now trading at $1.23.
View the best growth stocks for 2022 here

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Adverum Biotechnologies

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) announced its quarterly earnings data on Thursday, May, 12th. The biotechnology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.04.
View Adverum Biotechnologies' earnings history

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the following people:
  • Dr. Laurent Fischer, Pres, CEO & Director (Age 58, Pay $921.08k) (LinkedIn Profile)
  • Mr. Kishor Peter Soparkar J.D., Chief Operating Officer (Age 51, Pay $622.55k)
  • Dr. Brigit Riley Ph.D., Chief Scientific Officer (Age 44, Pay $816.08k)
  • Mr. John W. Rakow J.D., Sr. VP, Gen. Counsel & Acting CFO (Age 65)
  • Ms. Nancy E. Pecota, Principal Accounting Officer (Age 62)
  • Mr. Heikki Jouttijarvi, Sr. VP & Head of Technical Operations
  • Ms. Dena House, Sr. VP of HR, Organizational Devel. & Learning
  • Ms. Carla Fiankan, Sr. VP of Regulatory Affairs
  • Dr. Jim Wang Ph.D., Chief Regulatory Officer
  • Mr. Thomas Kochy, Sr. VP and Head of Global Product Strategy & Commercial

What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?

3 employees have rated Adverum Biotechnologies CEO Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among Adverum Biotechnologies' employees.

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $1.23.

How much money does Adverum Biotechnologies make?

Adverum Biotechnologies (NASDAQ:ADVM) has a market capitalization of $121.49 million and generates $7.50 million in revenue each year. The biotechnology company earns $-145,540,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis.

How many employees does Adverum Biotechnologies have?

Adverum Biotechnologies employs 188 workers across the globe.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The official website for Adverum Biotechnologies is www.adverum.com. The biotechnology company can be reached via phone at (650) 656-9323, via email at mlacy@adverum.com, or via fax at 650-329-8151.

This page (NASDAQ:ADVM) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.